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The success of B cell-directed therapy in patients with multiple sclerosis (MS) has been highlighted and demonstrates the essential role these cells have in the pathogenesis of MS. 1 The chimeric anti-CD20 monoclonal antibody (mAb) rituximab (RTX) was the first anti-CD20 to be licensed for use in humans. RTX has shown promise in phase II clinical trials in relapsing remitting multiple sclerosis (RRMS) 2 as well as observational MS trials. 3, 4 More recently, the humanized anti-CD20 mAb ocrelizumab (OCR) was tested in phase III trials for relapsing MS and primary progressive multiple sclerosis (PPMS). 5, 6 These pivotal trials provided the support for the US Food and Drug Administration (FDA) to license OCR for both PPMS and relapsing forms of MS in March 2017.
Controversy has arisen as to whether RTX should be an acceptable replacement for OCR. While there is an FDA indication for RTX in the US for specific malignancies and rheumatoid arthritis, the use of RTX as an MS therapy would be considered "off-label." Arguments have been made regarding equivalent efficacy, safety, and convenience between RTX and OCR. However, there is a significant difference in cost, which is substantially lower for RTX. The author contrasts the use of RTX and OCR for MS within these topical areas to show the unique niche for OCR at the present time in the US health care system.
In terms of molecular structure, OCR binds to the extracellular loop of the CD20 epitope on B cells, 5 which is a different binding site than RTX. 5, 7 Both mAbs differ in the mechanism for depleting B cells. OCR has a higher capacity for antibody-dependent cellular cytotoxicity and weaker complement-dependent cytotoxicity compared with RTX. OCR, thereby, provides a more direct path for eliminating B cells which could make OCR a more effective agent with less untoward effects on the immune system.
When examining efficacy for relapsing MS, clinical trials using RTX have shown consistent and significant reductions in relapse rates, T2 and contrast enhancing magnetic resonance imaging (MRI) lesions. 2, 3, 8 An annualized relapse rate of 0.044 was found in a recent observational trial of RTX in a large cohort of patients with RRMS. 3 While much larger in scope, the phase III MS studies using OCR showed a 47% absolute risk reduction (ARR) (0.16 in OCR group) compared with interferon beta 1a and significant reduction in T2 and contrast enhancing MRI lesions. 5 An additional 40% relative risk reduction in confirmed disability progression sustained at 3 months was also demonstrated. Direct comparisons between RTX and OCR are difficult because of the differences in trial designs. Nevertheless, relapse reductions and improvement in inflammatory MRI lesions are robust in recent MS trials for both RTX and OCR.
For PPMS, the primary outcome for the randomized placebo-controlled trials was confirmed disability progression for 12 weeks (CDP12) based on the Expanded Disability Status Scale (EDSS). In the Phase II RTX PPMS trial, there was no significant difference in the time to CDP12 at 96 weeks (hazard ratio (HR) 0.77, p = 0.14). 9 In a pre-planned subgroup analysis, there were significant delays in CDP12 for patients aged <51 years and in those patients with gadoliniumenhancing lesions at baseline. The OCR Phase III PPMS trial demonstrated a modest but significant CDP12 at earlier time points (12 weeks, HR 0.75, p = 0.03, and 24 weeks, HR 0.75, p = 0.04). 6 Of note, the patient population in the OCR trial was younger, had a shorter disease during and was slightly less disabled based on the EDSS compared to the RTX trial.
Safety concerns are critical when making an MS disease modifying therapy choice. Infusion reactions and upper respiratory infections are the most common untoward effects overall for both RTX and OCR. Infusion reactions were most frequent at the first dose of RTX and OCR and occurred in up to 40%. Most were mild. RTX has been associated with severe and potentially fatal infusion reactions based on use in other medical conditions. A higher production of anti-drug antibodies was seen in RTX Phase II trial 2 as compared with OCR 5 implicating greater immunogenicity. No cases of progressive multifocal leukoencephalopathy (PML) have been reported in the literature in patients with MS receiving RTX or OCR to date. For comparison, the risk for PML in patients exposed to RTX with rheumatoid arthritis disease is low and estimated to be 1/25,000. 10 In terms of cancer risk, there was a higher rate of breast cancer and other malignancies in the OCR relapsing MS trial 5 and the PPMS trial. 6 Long term follow-up will be critical to monitor for cancers and other untoward effects.
The high and increasing cost of MS therapies in the United States has received a great deal of attention. 11 These trends are disturbing and more broad, reasonable solutions should be sought by providers, payers, and pharmaceutical manufacturers. The disparity in cost between RTX and OCR is significant, with RTX being markedly less expensive. At the same time, the FDA approval of OCR has opened up coverage by many health insurance companies for patients with relapsing and PPMS. RTX use for MS is variably covered depending on the health system and insurance company. The choice of RTX or OCR should be based on efficacy and safety issues. Although costlier than RTX, it can be argued that OCR is a more effective B cell-depleting agent with the potential for a greater likelihood of stabilizing MS activity in the right patient.
In sum, the current evidence shows that OCR has some unique features in its structure, therapeutic efficacy, and cost coverage options that make it a rational choice as opposed to RTX. Additional monitoring of outcomes and untoward effects of both OCR and RTX will be important to continue to identify risks and benefits. Ultimately, to resolve the issues around efficacy and safety between these two mAbs, a headto-head trial is required. Thankfully, investigators at the University of Colorado have launched such a study. 12 Further research into B cell-biology and B cell-depletion therapy in MS will provide more answers and enlighten the choice of therapies for MS.
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Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis -Commentary Bruce 
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Should lower cost alternate medications with comparable mechanisms of action, but without the proof from registration studies, be used in lieu of branded medications with proved efficacy and safety? Ocrelizumab is the first United States Food and Drug Administration-approved, humanized, B cell depleting, anti-CD20 (a glycosylated phosphoprotein expressed on the surface of B cells that may act as a calcium channel) monoclonal antibody treatment for relapsing and primary progressive forms of multiple sclerosis. Rituximab is a chimeric antibody that also targets CD20 and depletes B cells with comparable efficiency. If one believes that B cell depletion is the mechanism whereby ocrelizumab exerts its beneficial effects in multiple sclerosis (MS), then both products should have similar efficacy.
Rituximab cannot be approved by some regulatory agencies due to the absence of registration studies with proof of efficacy on clinically meaningful endpoints. Regulatory agencies hold high efficacy standards so that only products with proved benefit are granted commercial license. However, clinicians may not require the same standards of proof for off-label use. Neurologists have extensive experience using medications when either there are no indicated treatments or when off-label therapies offer advantages over approved therapies.
A theoretical consideration in using branded medications over lower cost alternates is the argument that widespread use of low cost medications would reduce the incentive for industry to develop new products.
